To determine which glial cells may be the predominant site of TXNIP action in glaucomatous conditions, we examined the spatiotemporal consistency of glial activation and retinal inflammation levels in TXNIP-deficient and MCC950-treated COH mice. The gene discussed is TXNIP; the disease is retinitis.